- Home
- CLW vs KOD Comparison
CLW vs KOD Comparison
Compare CLW & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- KOD
- Stock Information
- Founded
- CLW 2005
- KOD 2009
- Country
- CLW United States
- KOD United States
- Employees
- CLW N/A
- KOD N/A
- Industry
- CLW Paper
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLW Basic Materials
- KOD Health Care
- Exchange
- CLW Nasdaq
- KOD Nasdaq
- Market Cap
- CLW 501.0M
- KOD 454.7M
- IPO Year
- CLW N/A
- KOD 2018
- Fundamental
- Price
- CLW $31.06
- KOD $5.87
- Analyst Decision
- CLW Buy
- KOD Hold
- Analyst Count
- CLW 1
- KOD 4
- Target Price
- CLW $37.00
- KOD $8.00
- AVG Volume (30 Days)
- CLW 314.3K
- KOD 395.7K
- Earning Date
- CLW 02-13-2025
- KOD 03-27-2025
- Dividend Yield
- CLW N/A
- KOD N/A
- EPS Growth
- CLW N/A
- KOD N/A
- EPS
- CLW 0.88
- KOD N/A
- Revenue
- CLW $2,211,900,000.00
- KOD N/A
- Revenue This Year
- CLW N/A
- KOD N/A
- Revenue Next Year
- CLW N/A
- KOD N/A
- P/E Ratio
- CLW $34.79
- KOD N/A
- Revenue Growth
- CLW 58.65
- KOD N/A
- 52 Week Low
- CLW $23.97
- KOD $2.19
- 52 Week High
- CLW $57.13
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- CLW 52.23
- KOD 34.05
- Support Level
- CLW $30.22
- KOD $5.55
- Resistance Level
- CLW $33.27
- KOD $8.42
- Average True Range (ATR)
- CLW 0.97
- KOD 0.61
- MACD
- CLW -0.15
- KOD -0.27
- Stochastic Oscillator
- CLW 36.80
- KOD 4.72
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and selling of private label tissue, paperboard, and pulp-based products. The company has two reportable segments namely the consumer products segment which manufactures and sells a complete line of at-home tissue products as well as AFH products. The pulp and paperboard segment manufactures and markets bleached paperboard for the high-end segment of the packaging industry as well as offers services that include custom sheeting, slitting and cutting of paperboard. It generates maximum revenue from Pulp and Paperboard segment. Geographically, it derives maximum revenue from the United States.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.